Skip to main content
RSC Medicinal Chemistry logoLink to RSC Medicinal Chemistry
. 2024 Jan 29;15(2):753–754. doi: 10.1039/d4md90004a

Correction: A high-throughput effector screen identifies a novel small molecule scaffold for inhibition of ten-eleven translocation dioxygenase 2

Shubhendu Palei a, Jörn Weisner a, Melina Vogt a, Rajesh Gontla a, Benjamin Buchmuller a, Christiane Ehrt a, Tobias Grabe a, Silke Kleinbölting a, Matthias Müller a, Guido H Clever a,, Daniel Rauh a,, Daniel Summerer a,
PMCID: PMC10880909  PMID: 38389879

Abstract

Correction for ‘A high-throughput effector screen identifies a novel small molecule scaffold for inhibition of ten-eleven translocation dioxygenase 2’ by Shubhendu Palei et al., RSC Med. Chem., 2022, 13, 1540–1548, https://doi.org/10.1039/D2MD00186A.


The authors would like to correct the activity data reported in Table 1 and adjust the associated conclusions. Compound 2, a simple sulfonic acid-based quinoline scaffold, was synthesized via hydrolysis of the corresponding sulfonic acid chloride, and an IC50 of 2.3 μM for the inhibition of the iron/αKG-dependent dioxygenase hTET2 was obtained from a MALDI-based inhibition assay. Compound 2 is structurally related to the known broad-spectrum iron/αKG-dependent dioxygenase inhibitor IOX-1 that features an iron-chelating 8-hydroxyquinoline (8HQ) core. In contrast, 2 bears a fluorine substituent in the 8-position that is expected to significantly attenuate iron affinity (supported by DFT calculations). This led to the conclusion that 2 acts as an isostere of IOX1 with low iron affinity, making it a starting point for TET2 inhibitors without this property. However, a later re-synthesis of 2 using a different starting material yielded an inactive compound. After consultation with the manufacturer, the authors suspect trace impurities of undefined polychlorinated quinoline species in the sulfonic acid chloride to be responsible for the observed activity, but attempts to purify these impurities proved unsuccessful. The authors thus conclude that the activity data of the compounds obtained via this sulfonic acid chloride are not trustable, and apologize for any confusion this data may have caused.

Structure–activity relationship (SAR).

graphic file with name d4md90004a-u1.jpg
Compound ID R1 IC50 (μM) Compound ID R1 IC50 (μM)
1 graphic file with name d4md90004a-u2.jpg >200 13 graphic file with name d4md90004a-u3.jpg >200
2 graphic file with name d4md90004a-u4.jpg >200 14 graphic file with name d4md90004a-u5.jpg >200
3 graphic file with name d4md90004a-u6.jpg >200 15 graphic file with name d4md90004a-u7.jpg >200
4 graphic file with name d4md90004a-u8.jpg >200 16 graphic file with name d4md90004a-u9.jpg >200
5 graphic file with name d4md90004a-u10.jpg >200 17 graphic file with name d4md90004a-u11.jpg >200
6 graphic file with name d4md90004a-u12.jpg >200 18 12.1 ± 4.2
7 graphic file with name d4md90004a-u13.jpg >200 19 >200a
8 graphic file with name d4md90004a-u14.jpg >200 20 170 ± 25a
9 graphic file with name d4md90004a-u15.jpg >200 21 8.6a
10 graphic file with name d4md90004a-u16.jpg >200 22 48.6
11 graphic file with name d4md90004a-u17.jpg >200 IOX1 2.3 ± 0.6
12 graphic file with name d4md90004a-u18.jpg >200
a

Only one replicate was performed.

The authors conducted additional SAR, revealing that the sulfonic acid group of 2 can replace the carboxyl group of IOX1, leading to a simple sulfonic acid-based quinoline 18 with a virtually identical IC50. In contrast, a replacement of IOX1's 8-hydroxyl group with a fluorine atom led to inactivity (19). The authors further identified and validated other IOX1-derived compounds without the 8HQ core that nevertheless showed micromolar IC50 values, such as isoquinoline-3-carboxylic acid (20), tetrahydroisoquinoline-6,7-diol (21), and 3-hydroxypicolinic acid (22). This combined data indicates that the 8HQ core is essential for hTET2 inhibition by IOX1 itself, whereas it is not essential for IOX1-derived compounds in general, providing new starting points for TET2 inhibitors without the 8HQ core.

An updated version of Table 1 is included here.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

Supplementary Material


Articles from RSC Medicinal Chemistry are provided here courtesy of Royal Society of Chemistry

RESOURCES